OptimizeRx returns to profit with $5.1M net income; sales team doubles, debt cut 23%

Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~2 min read

Key Changes

• high

  Company returned to profitability in FY2025 with $5.1M net income vs. $20.1M loss in FY2024, driven by 19% revenue growth to $109.4M, gross margin expansion to 67.3%, and 15% operating expense reduction (lower stock-based comp, no goodwill impairment).

  MD&A: Profitability & Operating Results verify on EDGAR →
• high

  Operating cash flow surged to $18.7M from $4.9M, enabling $8M in debt reduction (term loan now $26.3M, down 23%) and $10M cash build. Board authorized new $10M share repurchase program through March 2027; term loan maturity extended to Oct 2029.

  MD&A: Cash Flow & Capital Allocation verify on EDGAR →
• high

  Revenue from top-20 pharma manufacturers fell to 52% of total (from 65%), while three customers now exceed 10% of revenue (vs. two prior year). Channel partner concentration rose to 62% from 57%, heightening dependency on two eRx/EHR platforms.

  MD&A & Risk Factors: Customer Concentration verify on EDGAR →